Paratek Pharmaceuticals, Inc.
PRTK · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $151 | $121 | $44 | $17 |
| % Growth | 24.7% | 177.9% | 163% | – |
| Cost of Goods Sold | $23 | $22 | $9 | $3 |
| Gross Profit | $128 | $99 | $35 | $13 |
| % Margin | 84.7% | 82.2% | 80.1% | 78.9% |
| R&D Expenses | $38 | $30 | $24 | $40 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $146 | $119 | $90 | $89 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$9 | -$9 | -$3 | -$0 |
| Operating Expenses | $174 | $141 | $110 | $129 |
| Operating Income | -$46 | -$41 | -$76 | -$116 |
| % Margin | -30.6% | -34% | -173.5% | -698.9% |
| Other Income/Exp. Net | -$17 | -$17 | -$21 | -$13 |
| Pre-Tax Income | -$64 | -$58 | -$97 | -$128 |
| Tax Expense | $0 | $1 | $20 | $0 |
| Net Income | -$64 | -$59 | -$116 | -$129 |
| % Margin | -42.2% | -48.8% | -267.2% | -778.5% |
| EPS | -1.17 | -1.22 | -2.63 | -3.93 |
| % Growth | 4.1% | 53.6% | 33.1% | – |
| EPS Diluted | -1.17 | -1.22 | -2.63 | -3.93 |
| Weighted Avg Shares Out | 54 | 48 | 44 | 33 |
| Weighted Avg Shares Out Dil | 54 | 48 | 44 | 33 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $2 | $4 |
| Interest Expense | $18 | $17 | $20 | $16 |
| Depreciation & Amortization | $1 | $0 | $2 | $4 |
| EBITDA | -$45 | -$41 | -$74 | -$109 |
| % Margin | -29.8% | -33.6% | -169.9% | -656.1% |